User login
Key clinical point: Children hospitalized with migraine showed a high prevalence of psychiatric comorbidities, the presence of which was associated with increased medication use, a longer length of stay (LOS), and increased readmission.
Major finding: Psychiatric comorbidities were prevalent in 32% of children hospitalized for migraine headaches, with the prevalence of anxiety (11.2%), depression (6.7%), and attention-deficit/hyperactivity disorder (6.5%) being the highest. Children with vs. without psychiatric comorbidity were significantly more likely to receive dihydroergotamine, topiramate, and valproate, and had a longer mean LOS and higher 30-day readmission (all P < .001).
Study details: This multicenter, retrospective, cohort study included 21,436 children aged 6-18 years who were hospitalized for migraine headache.
Disclosures: No funding was received for this study. The authors declared no conflict of interests.
Source: Kafle M et al. Association of psychiatric comorbidities with treatment and outcomes in pediatric migraines. Hosp Pediatr. 2022;12(3):e101-e105 (Feb 14). Doi: 10.1542/hpeds.2021-006085
Key clinical point: Children hospitalized with migraine showed a high prevalence of psychiatric comorbidities, the presence of which was associated with increased medication use, a longer length of stay (LOS), and increased readmission.
Major finding: Psychiatric comorbidities were prevalent in 32% of children hospitalized for migraine headaches, with the prevalence of anxiety (11.2%), depression (6.7%), and attention-deficit/hyperactivity disorder (6.5%) being the highest. Children with vs. without psychiatric comorbidity were significantly more likely to receive dihydroergotamine, topiramate, and valproate, and had a longer mean LOS and higher 30-day readmission (all P < .001).
Study details: This multicenter, retrospective, cohort study included 21,436 children aged 6-18 years who were hospitalized for migraine headache.
Disclosures: No funding was received for this study. The authors declared no conflict of interests.
Source: Kafle M et al. Association of psychiatric comorbidities with treatment and outcomes in pediatric migraines. Hosp Pediatr. 2022;12(3):e101-e105 (Feb 14). Doi: 10.1542/hpeds.2021-006085
Key clinical point: Children hospitalized with migraine showed a high prevalence of psychiatric comorbidities, the presence of which was associated with increased medication use, a longer length of stay (LOS), and increased readmission.
Major finding: Psychiatric comorbidities were prevalent in 32% of children hospitalized for migraine headaches, with the prevalence of anxiety (11.2%), depression (6.7%), and attention-deficit/hyperactivity disorder (6.5%) being the highest. Children with vs. without psychiatric comorbidity were significantly more likely to receive dihydroergotamine, topiramate, and valproate, and had a longer mean LOS and higher 30-day readmission (all P < .001).
Study details: This multicenter, retrospective, cohort study included 21,436 children aged 6-18 years who were hospitalized for migraine headache.
Disclosures: No funding was received for this study. The authors declared no conflict of interests.
Source: Kafle M et al. Association of psychiatric comorbidities with treatment and outcomes in pediatric migraines. Hosp Pediatr. 2022;12(3):e101-e105 (Feb 14). Doi: 10.1542/hpeds.2021-006085